Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics (NASDAQ: TVTX) announced that on September 10, 2024, its Compensation Committee granted inducement equity grants to six new employees. These grants consist of restricted stock units (RSUs) covering a total of 33,500 shares of common stock. The RSUs were granted outside of Travere's 2018 Equity Incentive Plan but are subject to its terms. They were provided as inducements for new employees joining Travere, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs have a four-year vesting schedule, with 25% of the shares vesting annually on the grant date anniversary, contingent on the employee's continued service with Travere.
Travere Therapeutics (NASDAQ: TVTX) ha annunciato che il 10 settembre 2024 il suo Comitato per la Retribuzione ha concesso assegnazioni azionarie di incentivazione a sei nuovi dipendenti. Queste assegnazioni consistono in unità azionarie vincolate (RSUs) che coprono un totale di 33.500 azioni ordinarie. Le RSUs sono state concesse al di fuori del Piano di Incentivazione Azionaria del 2018 di Travere, ma sono soggette ai suoi termini. Sono state fornite come incentivi per i nuovi dipendenti che si uniscono a Travere, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le RSUs hanno un programma di maturazione di quattro anni, con il 25% delle azioni che maturano annualmente nell'anniversario della data di concessione, a condizione che il dipendente continui a prestare servizio in Travere.
Travere Therapeutics (NASDAQ: TVTX) anunció que el 10 de septiembre de 2024, su Comité de Compensación otorgó subsidios de acciones por incentivos a seis nuevos empleados. Estos subsidios consisten en unidades de acciones restringidas (RSUs) que cubren un total de 33,500 acciones ordinarias. Las RSUs se otorgaron fuera del Plan de Incentivos de Acciones 2018 de Travere, pero están sujetas a sus términos. Se proporcionaron como incentivos para los nuevos empleados que se unen a Travere, cumpliendo con la Regla de Cotización de Nasdaq 5635(c)(4). Las RSUs tienen un cronograma de consolidación de cuatro años, con el 25% de las acciones consolidándose anualmente en el aniversario de la fecha de concesión, condicionado al servicio continuo del empleado en Travere.
Travere Therapeutics (NASDAQ: TVTX)는 2024년 9월 10일, 보상 위원회가 여섯 명의 새로운 직원에게 유도 주식 보상을 제공했다고 발표했습니다. 이 보상은 총 33,500주에 해당하는 제한된 주식 단위(RSUs)로 구성되어 있습니다. RSUs는 Travere의 2018 주식 인센티브 계획 외부에서 부여되었지만 해당 조건에 따라야 합니다. 새로운 직원이 Travere에 합류할 때 유인을 제공하기 위해 제공되었으며, Nasdaq 상장 규칙 5635(c)(4)을 준수합니다. RSUs는 4년의 베스팅 일정이 있으며, 25%의 주식이 부여일 연도에 연간으로 베스트되고, 이는 직원의 Travere에 대한 지속적인 서비스에 따라 달라집니다.
Travere Therapeutics (NASDAQ: TVTX) a annoncé que le 10 septembre 2024, son Comité de Rémunération a accordé des attributions d'actions incitatives à six nouveaux employés. Ces attributions consistent en unités d'actions restreintes (RSUs) couvrant un total de 33 500 actions ordinaires. Les RSUs ont été accordées en dehors du Plan d'Incitation en Actions 2018 de Travere, mais sont soumises à ses modalités. Elles ont été fournies comme incitations pour les nouveaux employés rejoignant Travere, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les RSUs ont un calendrier d'acquisition de quatre ans, avec 25 % des actions acquises annuellement à chaque anniversaire de la date d'attribution, sous réserve de la continuité du service de l'employé chez Travere.
Travere Therapeutics (NASDAQ: TVTX) gab bekannt, dass am 10. September 2024 sein Vergütungsausschuss Anreizaktienzuschüsse an sechs neue Mitarbeiter gewährt hat. Diese Zuschüsse bestehen aus eingeschränkten Aktieneinheiten (RSUs), die insgesamt 33.500 Stammaktien abdecken. Die RSUs wurden außerhalb des Equity Incentive Plans von Travere aus dem Jahr 2018 gewährt, unterliegen jedoch den Bedingungen dieses Plans. Sie wurden als Anreiz für neue Mitarbeiter, die zu Travere kommen, bereitgestellt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs haben einen Vesting-Plan von vier Jahren, wobei 25 % der Aktien jährlich am Jahrestag der Gewährung verfallen, abhängig von der fortwährenden Dienstleistung des Mitarbeiters bei Travere.
- Travere is attracting new talent by offering equity incentives
- The company is aligning employee interests with shareholder interests through stock-based compensation
- Potential dilution of existing shareholders' stake due to the issuance of new shares
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years, with
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact Info
| Media: 888-969-7879 mediarelations@travere.com | Investors: 888-969-7879 IR@travere.com |
FAQ
How many new employees received inducement grants from Travere Therapeutics (TVTX) on September 10, 2024?
What type of equity grants did Travere Therapeutics (TVTX) issue to new employees?
How many shares of common stock are covered by the RSUs granted by Travere Therapeutics (TVTX)?
What is the vesting schedule for the RSUs granted by Travere Therapeutics (TVTX)?
